CN104211716A - 雷帕霉素的制备方法 - Google Patents

雷帕霉素的制备方法 Download PDF

Info

Publication number
CN104211716A
CN104211716A CN201410391783.0A CN201410391783A CN104211716A CN 104211716 A CN104211716 A CN 104211716A CN 201410391783 A CN201410391783 A CN 201410391783A CN 104211716 A CN104211716 A CN 104211716A
Authority
CN
China
Prior art keywords
compound
alkyl
formula
group
arylthiono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410391783.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿克莫格鲁
S·普费弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104211716A publication Critical patent/CN104211716A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201410391783.0A 2006-01-24 2007-01-22 雷帕霉素的制备方法 Pending CN104211716A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0601406.2 2006-01-24
GBGB0601406.2A GB0601406D0 (en) 2006-01-24 2006-01-24 Organic Compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800034190A Division CN101374847A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法

Publications (1)

Publication Number Publication Date
CN104211716A true CN104211716A (zh) 2014-12-17

Family

ID=36060760

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410391783.0A Pending CN104211716A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法
CNA2007800034190A Pending CN101374847A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007800034190A Pending CN101374847A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法

Country Status (11)

Country Link
US (1) US8138344B2 (enExample)
EP (1) EP1979359A1 (enExample)
JP (2) JP5416412B2 (enExample)
KR (1) KR101423343B1 (enExample)
CN (2) CN104211716A (enExample)
AU (1) AU2007209569B2 (enExample)
BR (1) BRPI0707330A2 (enExample)
CA (1) CA2637075A1 (enExample)
GB (1) GB0601406D0 (enExample)
RU (1) RU2448970C2 (enExample)
WO (1) WO2007085400A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
JP6378192B2 (ja) * 2012-11-13 2018-08-22 エルジー エレクトロニクス インコーポレイティド データ送信方法及び装置、並びにデータ送信方法及び装置
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
EP3109250A1 (en) * 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
LT3898637T (lt) 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
KR20260115158A (ko) 2019-03-26 2026-07-23 노파르티스 아게 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
WO2026080482A1 (en) * 2024-10-07 2026-04-16 Tornado Therapeutics, Inc. Rapamycin derivatives and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
US8138344B2 (en) 2012-03-20
RU2008134424A (ru) 2010-02-27
WO2007085400A1 (en) 2007-08-02
JP2009523836A (ja) 2009-06-25
BRPI0707330A2 (pt) 2011-05-03
JP5416412B2 (ja) 2014-02-12
RU2448970C2 (ru) 2012-04-27
GB0601406D0 (en) 2006-03-08
US20090012298A1 (en) 2009-01-08
KR101423343B1 (ko) 2014-07-24
CN101374847A (zh) 2009-02-25
EP1979359A1 (en) 2008-10-15
JP2013136631A (ja) 2013-07-11
KR20080090453A (ko) 2008-10-08
AU2007209569A1 (en) 2007-08-02
AU2007209569B2 (en) 2011-09-15
CA2637075A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
CN1829722B (zh) 区域选择性合成cci-779
JP5416412B2 (ja) ラパマイシン誘導体の製造方法
EP2670756B1 (en) Process for making everolimus
KR101818267B1 (ko) 엔테카비르와 그 중간체를 제조하는 방법
KR20150074062A (ko) 담즙산 유도체의 제조 방법
HUT62299A (en) Process for producing rapamycinsilyl ethers
EP3953339B1 (en) Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
WO2016020664A1 (en) Process for the synthesis of everolimus and intermediates thereof
JPS62187485A (ja) 24,25−エポキシコレステロ−ル類の製造法
JP5492786B2 (ja) ゼラレノンマクロライドアナログを作製するための中間体および方法
ES2881899T3 (es) Procedimiento de preparación de un inhibidor de fosfodiesterasa 4
CA2630645A1 (en) Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
CN111793047B (zh) 一种艾日布林中间体的制备方法
JP3228488B2 (ja) 20−エピステロイド誘導体およびその製造方法
CN116535363B (zh) 碘叶立德参与的三组分环加成构建异恶唑烷衍生物的合成方法
MX2008009469A (en) Process for the preparation of rapamycin derivatives
JP4499847B2 (ja) ミルベマイシン類の13−エステル誘導体の製造法
CA2222785C (en) Vitamin d analogues
CN109928968B (zh) 一类制备抗癌药物的中间体
AU2011254079A1 (en) Process for the preparation of rapamycin derivatives
WO2016022519A1 (en) Stereochemically defined polypropionates and methods for making and using the same
WO2003080604A1 (en) Dihydroisoxazolyl substituted tetrahydrofuran coompounds as intermediates in the preparation of 2-(purin-9-yl) - tetrahydrofuran derivatives
WO2017182465A1 (en) Process for the preparation of bimatoprost
EA007741B1 (ru) Способ получения 2-(замещенный фенил)-2-гидроксиэтилкарбаматов

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141217